Sialadenitis
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
signs of airway compromise
secure airway
Airway compromise may be due to acute glandular swelling. The establishment of an open airway is essential for any patient with worsening airway compromise. Surgical airway may be required if intubation is unsuccessful. Elevating the head of the bed may help temporarily, but careful monitoring is crucial.
broad-spectrum antibiotic
Treatment recommended for ALL patients in selected patient group
Intravenous antibiotics are recommended for the first 48 hours, then consider an oral alternative if clinically improving.
If a patient is intolerant of beta-lactam antibiotics or vancomycin, clindamycin or metronidazole are alternative options. Cephalosporins and fluoroquinolones (e.g., moxifloxacin) have been identified by a systematic review to have particularly favorable pharmacokinetics in saliva.[41]Troeltzsch M, Pache C, Probst FA, et al. Antibiotic concentrations in saliva: a systematic review of the literature, with clinical implications for the treatment of sialadenitis. J Oral Maxillofac Surg. 2014;72:67-75. http://www.joms.org/article/S0278-2391(13)00820-3/fulltext http://www.ncbi.nlm.nih.gov/pubmed/23992785?tool=bestpractice.com Fluoroquinolones should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended due to the risk of serious, disabling, and potentially irreversible adverse effects, including tendonitis, tendon rupture, arthralgia, neuropathies, and other musculoskeletal or nervous system effects.[42]European Medicines Agency. Quinolone and fluoroquinolone-containing medicinal products. November 2018 [internet publication]. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products [43]Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. March 2019 [internet publication]. https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects [44]Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. December 2016 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
Primary options
cefuroxime axetil: 1.5 g intravenously every 8 hours
OR
vancomycin: 500 mg intravenously every 6 hours
OR
amoxicillin/clavulanate: 875 mg orally twice daily
OR
cephalexin: 500 mg orally four times daily
Secondary options
clindamycin: 900 mg intravenously every 8 hours; or 300 mg orally three times daily
OR
nafcillin: 1-2 g intravenously every 4 hours
OR
oxacillin: 500 mg intravenously every 6 hours
OR
metronidazole: 500 mg orally/intravenously every 8 hours
Tertiary options
moxifloxacin: 400 mg intravenously/orally every 24 hours
intravenous fluids
Treatment recommended for ALL patients in selected patient group
Patients with airway compromise will require intravenous replacement therapy to meet their daily requirements and to account for any extra fluid losses due to pyrexia. Normal saline is usually the first choice, but fluid therapy should be tailored to the individual patient and department guidelines on the use of colloid and crystalloid fluids.
acute bacterial sialadenitis (nonobstructive)
broad-spectrum intravenous or oral antibiotic
Empiric broad-spectrum antibiotic therapy should be started pending sensitivity results based on cultures. If a patient is intolerant of beta-lactam antibiotics or vancomycin, clindamycin or metronidazole are alternative options. Cephalosporins and fluoroquinolones (e.g., moxifloxacin) have been identified by a systematic review to have particularly favorable pharmacokinetics in saliva.[41]Troeltzsch M, Pache C, Probst FA, et al. Antibiotic concentrations in saliva: a systematic review of the literature, with clinical implications for the treatment of sialadenitis. J Oral Maxillofac Surg. 2014;72:67-75. http://www.joms.org/article/S0278-2391(13)00820-3/fulltext http://www.ncbi.nlm.nih.gov/pubmed/23992785?tool=bestpractice.com Fluoroquinolones should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended due to the risk of serious, disabling, and potentially irreversible adverse effects, including tendonitis, tendon rupture, arthralgia, neuropathies, and other musculoskeletal or nervous system effects.[42]European Medicines Agency. Quinolone and fluoroquinolone-containing medicinal products. November 2018 [internet publication]. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products [43]Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. March 2019 [internet publication]. https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects [44]Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. December 2016 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
Either intravenous or oral antibiotics may be used. In significant infection (fever, trismus, or cranial nerve involvement) intravenous antibiotics are usually given for the first 48 hours, then may be continued or switched to an oral alternative if clinically improved and fever has resolved. If the patient is apyrexial and cranial nerves are unaffected, then outpatient antibiotic therapy is usually sufficient, but review at 24 hours is recommended.
Patients with fever, trismus, or cranial nerve involvement will need careful observation for impending airway compromise. All patients treated on outpatient basis should be re-examined within 24 hours for worsening symptoms or signs.
Treatment course: 7 days total.
Primary options
cefuroxime axetil: 1.5 g intravenously every 8 hours
OR
vancomycin: 500 mg intravenously every 6 hours
OR
amoxicillin/clavulanate: 875 mg orally twice daily
OR
cephalexin: 500 mg orally four times daily
Secondary options
clindamycin: 900 mg intravenously every 8 hours; or 300 mg orally three times daily
OR
nafcillin: 1-2 g intravenously every 4 hours
OR
oxacillin: 500 mg intravenously every 6 hours
OR
metronidazole: 500 mg orally/intravenously every 8 hours
Tertiary options
moxifloxacin: 400 mg intravenously/orally every 24 hours
conservative management (hydration, pain relief, and sialogogues)
Treatment recommended for ALL patients in selected patient group
Acute medical treatment for bacterial sialadenitis includes conservative therapies such as hydration, analgesia, sialogogues (e.g. pilocarpine, cevimeline) to stimulate salivary secretion, and regular, gentle gland massage. Some patients find that the topical application of ice cubes provides some relief. Temporary comfort can be obtained by sipping water and other sugar-free liquids.
Primary options
ibuprofen: 400-600 mg orally every 4-6 hours when required, maximum 2400 mg/day
or
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
-- AND --
pilocarpine: 5 mg orally three times daily
or
cevimeline: 30 mg orally three times daily
corticosteroid
Treatment recommended for SOME patients in selected patient group
If soft tissue swelling is significant and there are no contraindications, corticosteroid therapy may be given in addition to antibiotics and analgesia.[47]Marchal F, Bradley PJ. Treatment of infections and inflammatory conditions. In: Management of infections of the salivary glands. Berlin, Germany: Springer Berlin Heidelberg. 2007:169-176.
Primary options
dexamethasone sodium phosphate: consult specialist for guidance on dose
surgical drainage
Treatment recommended for SOME patients in selected patient group
If an abscess is identified, this may require surgical incision and drainage. Surgical intervention should be considered for mature fluctuant abscesses
Location of the abscess dictates the surgical approach. In the submandibular gland, an intraoral approach, an extraoral approach, or a combination of approaches may be appropriate. In parotid abscesses, an external approach is usually necessary. Care must be taken to avoid injury to the facial nerve.
obstructive sialadenitis
conservative management (hydration, pain relief, and sialogogues)
Acute medical treatment for obstructive sialadenitis includes conservative therapies such as hydration, analgesia, sialogogues (e.g. pilocarpine, cevimeline) to stimulate salivary secretion, and regular, gentle gland massage. Some patients find that the topical application of ice cubes provides some relief. Temporary comfort can be obtained by sipping water and other sugar-free liquids.
Primary options
ibuprofen: 400-600 mg orally every 4-6 hours when required, maximum 2400 mg/day
or
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
-- AND --
pilocarpine: 5 mg orally three times daily
or
cevimeline: 30 mg orally three times daily
interventional stone removal
Treatment recommended for SOME patients in selected patient group
In patients with sialolithiasis, surgical intervention to remove the stone from the ductal system may be necessary. Location of the stone dictates the procedure.
Interventional sialendoscopy using a semirigid endoscope with irrigation is increasingly used as a first-line therapy for stones in the distal ducts for both the submandibular and parotid glands.[48]National Institute for Health and Care Excellence. Therapeutic sialendoscopy - Interventional procedures guidance [IPG218]. May 2007 [internet publication]. https://www.nice.org.uk/guidance/ipg218/chapter/1-Guidance One meta-analysis found that sialendoscopy is safe, efficacious, and gland-preserving.[49]Strychowsky JE, Sommer DD, Gupta MK, et al. Sialendoscopy for the management of obstructive salivary gland disease: A systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg. 2012;138:541-547. http://www.ncbi.nlm.nih.gov/pubmed/22710505?tool=bestpractice.com This approach has also been described for retrieval of foreign bodies.[50]Su YX, Lao XM, Zheng GS, et al. Sialoendoscopic management of submandibular gland obstruction caused by intraglandular foreign body. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:e17-e21. http://www.ncbi.nlm.nih.gov/pubmed/23083482?tool=bestpractice.com
Alternatively, if the sialolith is considered accessible to direct removal, then slitting of the salivary duct with cannulation and direct stone removal should be considered. In the submandibular gland, calculi near the opening of the Wharton duct may be treated by cannulation of the duct and the stone removed via an intraoral approach. Approximately 40% of submandibular calculi can be managed this way. In a small number of cases, parotid gland calculi near the opening of the Stensen duct may be treated in a similar manner. However, the duct anatomy is such that postoperative stenosis may occur, so this procedure is rarely appropriate. Furthermore, the majority of parotid stones are more distal or within the intraglandular duct system and are not accessible to this approach.
Extracorporeal shock wave lithotripsy (ESWL) under ultrasonic guidance may be used for stones within the intraglandular duct system.[28]Kraaij S, Karagozoglu KH, Forouzanfar T, et al. Salivary stones: symptoms, aetiology, biochemical composition and treatment. Br Dent J. 2014 Dec 5;217(11):E23. https://www.nature.com/articles/sj.bdj.2014.1054 http://www.ncbi.nlm.nih.gov/pubmed/25476659?tool=bestpractice.com If a stone is removed then salivary gland massage should be carried out several times a day, combined with sialogogues to stimulate the salivary flow.[28]Kraaij S, Karagozoglu KH, Forouzanfar T, et al. Salivary stones: symptoms, aetiology, biochemical composition and treatment. Br Dent J. 2014 Dec 5;217(11):E23. https://www.nature.com/articles/sj.bdj.2014.1054 http://www.ncbi.nlm.nih.gov/pubmed/25476659?tool=bestpractice.com
broad-spectrum intravenous or oral antibiotic
Treatment recommended for ALL patients in selected patient group
Empiric broad-spectrum antibiotic therapy should be started pending sensitivity results based on cultures. If a patient is intolerant of beta-lactam antibiotics, clindamycin or metronidazole are alternative options. Cephalosporins and fluoroquinolones (e.g., moxifloxacin) have been identified by a systematic review to have particularly favorable pharmacokinetics in saliva.[41]Troeltzsch M, Pache C, Probst FA, et al. Antibiotic concentrations in saliva: a systematic review of the literature, with clinical implications for the treatment of sialadenitis. J Oral Maxillofac Surg. 2014;72:67-75. http://www.joms.org/article/S0278-2391(13)00820-3/fulltext http://www.ncbi.nlm.nih.gov/pubmed/23992785?tool=bestpractice.com Fluoroquinolones should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended due to the risk of serious, disabling, and potentially irreversible adverse effects, including tendonitis, tendon rupture, arthralgia, neuropathies, and other musculoskeletal or nervous system effects.[42]European Medicines Agency. Quinolone and fluoroquinolone-containing medicinal products. November 2018 [internet publication]. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products [43]Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. March 2019 [internet publication]. https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects [44]Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. December 2016 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
Either intravenous or oral antibiotics may be used. In significant infection (fever, trismus, or cranial nerve involvement) intravenous antibiotics are usually given for the first 48 hours, then may be continued or switched to an oral alternative if clinically improved and fever has resolved. If the patient is apyrexial and cranial nerves are unaffected, then outpatient antibiotic therapy is usually sufficient, but review at 24 hours is recommended.
Patients with fever, trismus, or cranial nerve involvement will need careful observation for impending airway compromise. All patients treated on an outpatient basis should be reexamined within 24 hours for worsening symptoms or signs.
Treatment course: 7 days total.
Primary options
cefuroxime axetil: 1.5 g intravenously every 8 hours
OR
amoxicillin/clavulanate: 875 mg orally twice daily
OR
cephalexin: 500 mg orally four times daily
Secondary options
clindamycin: 900 mg intravenously every 8 hours; or 300 mg orally three times daily
OR
metronidazole: 500 mg orally/intravenously every 8 hours
Tertiary options
moxifloxacin: 400 mg intravenously/orally every 24 hours
autoimmune sialadenitis
conservative management (hydration, pain relief, and sialogogues)
Acute medical treatment for symptomatic autoimmune sialadenitis includes conservative therapies such as hydration, analgesia, sialogogues (e.g. pilocarpine, cevimeline) to stimulate salivary secretion, and regular, gentle gland massage.
Salivary substitutes (artificial saliva) for improving lubrication and hydration of oral tissues may be used. Other alternatives include gels (fluoride gels), saliva-stimulating lozenges or chewing gums, mouthwashes, and prescription-strength toothpastes. Temporary comfort can be obtained by sipping water and other sugar-free liquids.
Primary options
ibuprofen: 400-600 mg orally every 4-6 hours when required, maximum 2400 mg/day
or
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
-- AND --
pilocarpine: 5 mg orally three times daily
or
cevimeline: 30 mg orally three times daily
treatment of underlying condition
Treatment recommended for ALL patients in selected patient group
Symptoms of autoimmune sialadenitis often improve following medical management of the underlying condition (such as Sjogren syndrome or IgG4-related disease).
subacute necrotizing sialadenitis
observation
Subacute necrotizing sialadenitis is rare but once confirmed usually resolves within 2 to 3 weeks and does not require further treatment.
chronic sialadenitis: recurrent or sclerosing (<3 times/year or nonsevere)
conservative management (hydration, pain relief, and sialogogues)
Chronic recurrent sialadenitis mainly presents in adults (only 10% of patients are children). It is typically tender, unilateral swelling of a major salivary gland of an episodic nature. It represents recurrent episodes of acute sialadenitis. This may be due to unresolved infection or underlying ductal anomalies.
Chronic sclerosing sialadenitis has a predilection for submandibular glands. Typically, it is a unilateral enlargement that may be symptomatic and clinically difficult to differentiate from a tumor.
Acute medical treatment for symptomatic chronic recurrent sialadenitis or chronic sclerosing sialadenitis includes conservative therapies such as hydration, analgesia, sialogogues (e.g. pilocarpine, cevimeline) to stimulate salivary secretion, and regular, gentle gland massage. Some patients find the topical application of ice cubes provides some relief. Temporary comfort can be obtained by sipping water and other sugar-free liquids.
Primary options
ibuprofen: 400-600 mg orally every 4-6 hours when required, maximum 2400 mg/day
or
naproxen: 250-500 mg orally twice daily when required, maximum 1250 mg/day
-- AND --
pilocarpine: 5 mg orally three times daily
or
cevimeline: 30 mg orally three times daily
broad-spectrum intravenous or oral antibiotic
Treatment recommended for ALL patients in selected patient group
Empiric broad-spectrum antibiotic therapy should be started pending sensitivity results based on cultures. If a patient is intolerant of beta-lactam antibiotics, clindamycin or metronidazole are alternative options. Cephalosporins and fluoroquinolones (e.g., moxifloxacin) have been identified by a systematic review to have particularly favorable pharmacokinetics in saliva.[41]Troeltzsch M, Pache C, Probst FA, et al. Antibiotic concentrations in saliva: a systematic review of the literature, with clinical implications for the treatment of sialadenitis. J Oral Maxillofac Surg. 2014;72:67-75. http://www.joms.org/article/S0278-2391(13)00820-3/fulltext http://www.ncbi.nlm.nih.gov/pubmed/23992785?tool=bestpractice.com Fluoroquinolones should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended due to the risk of serious, disabling, and potentially irreversible adverse effects, including tendonitis, tendon rupture, arthralgia, neuropathies, and other musculoskeletal or nervous system effects.[42]European Medicines Agency. Quinolone and fluoroquinolone-containing medicinal products. November 2018 [internet publication]. https://www.ema.europa.eu/en/medicines/human/referrals/quinolone-fluoroquinolone-containing-medicinal-products [43]Medicines and Healthcare products Regulatory Agency. Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects. March 2019 [internet publication]. https://www.gov.uk/drug-safety-update/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects [44]Food and Drug Administration. FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. December 2016 [internet publication]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
Either intravenous or oral antibiotics may be used. In significant infection (fever, trismus, or cranial nerve involvement) intravenous antibiotics are usually given for the first 48 hours, then may be continued or switched to an oral alternative if clinically improved and fever has resolved. If the patient is apyrexial and cranial nerves are unaffected, then outpatient antibiotic therapy is usually sufficient, but review at 24 hours is recommended.
Patients with fever, trismus, or cranial nerve involvement will need careful observation for impending airway compromise. All patients treated on outpatient basis should be re-examined within 24 hours for worsening symptoms or signs.
Treatment course: 7 days total.
Primary options
cefuroxime axetil: 1.5 g intravenously every 8 hours
OR
amoxicillin/clavulanate: 875 mg orally twice daily
OR
cephalexin: 500 mg orally four times daily
Secondary options
clindamycin: 900 mg intravenously every 8 hours; or 300 mg orally three times daily
OR
metronidazole: 500 mg orally/intravenously every 8 hours
Tertiary options
moxifloxacin: 400 mg intravenously/orally every 24 hours
recurrent sialadenitis: any cause (>3 times/year or severe attacks)
surgical excision of affected gland
Chronic recurrent sialadenitis and longstanding sialolithiasis may lead to salivary gland strophy, which predisposes to further episodes of an acute sialadenitis.
In patients with frequent (>3 times a year) or severe attacks, surgical excision of the affected gland should be considered.
In patients with symptomatic chronic sclerosing sialadenitis, removal of the affected gland is recommended. Recovery of function of the salivary gland is related to factors such as extent and severity of glandular infection, the diameter and number of the sialolith (if present), position of stones and the age of the patients.[28]Kraaij S, Karagozoglu KH, Forouzanfar T, et al. Salivary stones: symptoms, aetiology, biochemical composition and treatment. Br Dent J. 2014 Dec 5;217(11):E23. https://www.nature.com/articles/sj.bdj.2014.1054 http://www.ncbi.nlm.nih.gov/pubmed/25476659?tool=bestpractice.com
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer